SEVENFACT® to reduce bleeding in hemophilia with inhibitors
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A or hemophilia B and you have inhibitors
- You are at least 12 years old
- You (or your legal guardian) can understand the study and follow its rules
- You can provide records showing your past inhibitor levels
- You agree to record bleeding events and medicines using the study app or a paper diary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.